One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
  • Report Library
  • Who Trust Us
  • inquiry@market.us
  • +1 718 618 4351 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
  • Report Library
  • Who Trust Us
Home » Companies » Teva Pharmaceutical Industries Ltd. Company Profile

Teva Pharmaceutical Industries Ltd. Company Profile

logo

Teva Pharmaceutical Industries Ltd

Pharmaceutical Industry

  • Type

    Public

  • Headquarters

    Israel

  • Founded

    1901

  • Key Management

    Mr. Kåre Schultz (CEO)

  • Revenue

    ~15,878 (2021)

  • Headcount

    ~37,537 (2021)

  • Website

    www.tevapharm.com

Business Description

Teva Pharmaceutical Industries Ltd. is involved in the development and manufacture of medicines. It produces medicines for heart disease, pain relief, obesity, cancer, supportive care, infectious diseases, and human immunodeficiency virus. The company operates in the following geographic segments: North America and Europe. The company was established in Petah Tikva in Israel in 1901.

Key Financials

Revenue (US$ Mn):

  • US$ 15,878 Mn was the annual revenue generated by Teva Pharmaceutical Industries Ltd. in 2021
  • Teva Pharmaceutical Industries Ltd.’s annual revenue for 2020 was US$ 16,658 Mn, a -1.36% decrease from 2019
  • From 2018’s annual revenues, Teva Pharmaceutical Industries Ltd. registered a -10.43% decrease in 2019, amounting to US$ 16,887Mn
  • Total revenue of US$ 18,854 Mn was generated in 2018 by Teva Pharmaceutical Industries Ltd.

 

Operating Income (US$ Mn):

  • Teva Pharmaceutical Industries Ltd.’s operating income for 2021 was US$ 1,716 Mn, a -43.88% decrease from 2020
  • The operating income generated by Teva Pharmaceutical Industries Ltd. in 2020 was US$ 3,058 Mn
  • At a -5.16% decrease, Teva Pharmaceutical Industries Ltd.’s operating income of US$ 2,721 Mn was indexed in 2019
  • Teva Pharmaceutical Industries Ltd. generated an operating income of US$ 2,869 Mn in 2018

 

Net Income (US$ Mn):

  • US$ 417 Mn was the net income generated by Teva Pharmaceutical Industries Ltd. in 2021
  • Teva Pharmaceutical Industries Ltd.’s net income for 2020 was US$ -3,990 Mn, a 299.4% increase from 2019
  • From 2018’s net incomes, Teva Pharmaceutical Industries Ltd. registered a -53.53% decrease in 2019, amounting to US$ -999 Mn
  • A net income of US$ -2,150 Mn was generated in 2018 by Teva Pharmaceutical Industries Ltd.

Operating Margin %:

  • Teva Pharmaceutical Industries Ltd.’s operating margin for 2021 was 11%, a -41.3% decrease from 2020
  • The operating margin generated by Teva Pharmaceutical Industries Ltd. in 2020 was 18%
  • At a 5.92% increase, Teva Pharmaceutical Industries Ltd.’s operating margin of 16% was indexed in 2019
  • Teva Pharmaceutical Industries Ltd. generated an operating margin of 15% in 2018

 

Gross Margin %:

  • 48% was the gross margin generated by Teva Pharmaceutical Industries Ltd. in 2021
  • Teva Pharmaceutical Industries Ltd.’s gross margin for 2020 was 46%, a 4.04% increase from 2019
  • From 2018’s gross margins, Teva Pharmaceutical Industries Ltd. registered a 1.36% increase in 2019, amounting to 45%
  • A gross margin of 44% was generated in 2018 by Teva Pharmaceutical Industries Ltd.

 

SWOT Analysis

Strengths

Leading position in the global generics industry

Teva Pharmaceutical Industries Ltd. is involved in the development and manufacture of medicines. It produces medicines for heart disease, pain relief, obesity, cancer, supportive care, infectious diseases, and human immunodeficiency virus. The company operates in the following geographic segments: North America and Europe. The company was established in Petah Tikva in Israel in 1901.

Get this premium content

The Premium data is Locked
Buy Now to Unlock Premium Data

Table of Content

  1. Business Description
  2. Key Financials
  3. SWOT Analysis
    1. Strength
      1. Leading position in the global generics industry
      2. Strong R&D capabilities
      3. Liquidity position
    2. Weaknesses
      1. Decline in revenue
    3. Opportunities
      1. Increase in healthcare spending
      2. A positive outlook for the global generics market
      3. Strategic Initiatives
    4. Threats
      1. Increasing government scrutiny in the US and Europe
      2. Consolidation of customers
      3. Foreign exchange risks
    5. Key Developments
      1. Year 2021
      2. Year 2020
      3. Year 2019
      4. Year 2018
  • US $299
  • US $499
Buy Now
✖

Request For Company Data

We'll get back to you as quickly as possible

Primary Sidebar

  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
auto undefined
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sundanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • All Reports
  • All Sectors
  • Infographics
  • Statistics and Facts
  • Companies
  • Report Library

© 2025 Market.Us. All Rights Reserved.